We are live on
!
Find out more
YIH
Y-Intercept (HK) Portfolio holdings
AUM
$5.05B
1-Year Est. Return
17.89%
This Fund
S&P 500
This Quarter
Est. Return
+8.14%
1 Year Est. Return
+17.89%
3 Year Est. Return
+34.37%
5 Year Est. Return
+20.59%
10 Year Est. Return
–
AUM
$4.09B
AUM Growth
+$2.61B
(+177%)
Cap. Flow
+$2.46B
Cap. Flow
% of AUM
60.1%
Top 10 Holdings %
Top 10 Hldgs %
6.33%
Holding
2,105
New
963
Increased
487
Reduced
137
Closed
518
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$37.8M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$35.1M |
| 3 |
T-Mobile US
TMUS
|
+$30.4M |
| 4 |
Nu Holdings
NU
|
+$27.8M |
| 5 |
Consolidated Edison
ED
|
+$26.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arista Networks
ANET
|
+$17M |
| 2 |
Marvell Technology
MRVL
|
+$16.2M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$16.1M |
| 4 |
ServiceNow
NOW
|
+$13.3M |
| 5 |
Walmart Inc
WMT
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.87% |
| 2 | Industrials | 14.69% |
| 3 | Financials | 14.36% |
| 4 | Healthcare | 12.68% |
| 5 | Consumer Discretionary | 12.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Lineage Cell Therapeutics
LCTX
$264M
| $368K | 0.01% |
+405,043
| New | +$240K |
|
1302
GrafTech
EAF
$184M
| $366K | 0.01% |
+37,653
| New | +$333K |
|
1303
JPMorgan BetaBuilders Japan ETF
BBJP
$17B
| $365K | 0.01% |
+5,905
| New | +$344K |
|
1304
Bank of America
BAC
$429B
| $360K | 0.01% |
7,614
-84,616
| -92% | -$3.56M |
|
1305
SI-BONE Inc
SIBN
$818M
| $358K | 0.01% |
19,047
+7,512
| +65% | +$125K |
|
1306
Full House Resorts
FLL
$83.4M
| $358K | 0.01% |
+97,749
| New | +$327K |
|
|
GOOD
1307
Gladstone Commercial Corp
GOOD
$623M
| $358K | 0.01% |
+24,962
| New | +$354K |
|
1308
Invesco FTSE RAFI US 1000 ETF
PRF
$9.72B
| $357K | 0.01% |
+8,446
| New | +$337K |
|
1309
Maximus
MMS
$3.32B
| $357K | 0.01% |
5,085
-20,531
| -80% | -$1.44M |
|
1310
Agnico Eagle Mines
AEM
$72.2B
| $356K | 0.01% |
+2,992
| New | +$347K |
|
1311
iShares S&P Mid-Cap 400 Value ETF
IJJ
$8.83B
| $356K | 0.01% |
+2,879
| New | +$339K |
|
1312
CorVel
CRVL
$3.18B
| $354K | 0.01% |
+3,448
| New | +$380K |
|
1313
Xylem
XYL
$28.5B
| $354K | 0.01% |
+2,733
| New | +$331K |
|
1314
iShares MSCI Global Min Vol Factor ETF
ACWV
$3.34B
| $353K | 0.01% |
+2,981
| New | +$347K |
|
1315
W.P. Carey
WPC
$17B
| $353K | 0.01% |
+5,666
| New | +$349K |
|
|
TRML
1316
DELISTED
Tourmaline Bio
TRML
| $353K | 0.01% |
+22,056
| New | +$357K |
|
1317
iShares US Financials ETF
IYF
$4.65B
| $352K | 0.01% |
+2,906
| New | +$327K |
|
1318
Huazhu Hotels Group
HTHT
$13.3B
| $350K | 0.01% |
+10,316
| New | +$361K |
|
1319
Invesco S&P MidCap Momentum ETF
XMMO
$6.9B
| $349K | 0.01% |
2,717
-2,397
| -47% | -$286K |
|
1320
Life Time Group Holdings
LTH
$10.2B
| $349K | 0.01% |
+11,492
| New | +$341K |
|
1321
Spire Global
SPIR
$408M
| $345K | 0.01% |
+29,002
| New | +$293K |
|
1322
Globalstar
GSAT
$10.1B
| $343K | 0.01% |
+14,581
| New | +$294K |
|
1323
NN Inc
NNBR
$237M
| $343K | 0.01% |
+163,387
| New | +$325K |
|
1324
Ocular Therapeutix
OCUL
$1.83B
| $342K | 0.01% |
+36,815
| New | +$288K |
|
1325
Lightwave Logic
LWLG
$824M
| $340K | 0.01% |
+274,206
| New | +$288K |
|
Similar funds
HSA
O
LFG
JIM
CTC
NL
BPWM
VT
Y-Intercept (HK)'s Q2 2025 Portfolio in Review
As of Q2 2025, Y-Intercept (HK) held 2,105 positions worth $4.09B, up 177% from $1.48B the previous quarter. Its ten largest holdings account for 6.3% of the portfolio.
Y-Intercept (HK) deployed $2.46B of net new capital in Q2 2025, opening 963 new positions and adding to 487 existing holdings. Its largest new stake was Nu Holdings: 2,319,643 shares worth $31.8M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 19% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Novo Nordisk, an estimated $16.1M trimmed.
- Y-Intercept (HK)'s largest Q2 2025 buy was Nu Holdings: 2,319,643 shares worth $31.8M.
- Y-Intercept (HK) added most to UnitedHealth in Q2 2025, an estimated $37.8M increase.
- Y-Intercept (HK)'s biggest Q2 2025 reduction was Novo Nordisk, cutting an estimated $16.1M.
- Y-Intercept (HK) fully exited Arista Networks in Q2 2025, selling an estimated $17M.
- Y-Intercept (HK)'s ten largest holdings make up 6.3% of its $4.09B portfolio in Q2 2025.
- Y-Intercept (HK) opened 963 new positions and closed 518 in Q2 2025.
- Y-Intercept (HK)'s portfolio value rose 177% quarter-over-quarter to $4.09B.
Based on Y-Intercept (HK)'s 13F filing for Q2 2025, filed 1 Aug 2025.